Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shigella flexneri 2a-rEPAsucc
- Development stage
- Phase 3
- Lead developer
- National Institute of Child Health and Human Development
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Shigella flexneri 2a-rEPAsucc is a glycoconjugate vaccine candidate developed to prevent shigellosis caused by *Shigella flexneri* serotype 2a. The vaccine consists of the O-specific polysaccharide (O-SP) of *S. flexneri* 2a covalently linked to a recombinant Pseudomonas aeruginosa exoprotein A (rEPA) carrier protein. The 'succ' designation indicates the use of a succinic acid derivative (specifically succinic acid dihydrazide) as a linker or a succinylation modification to facilitate the conjugation of the polysaccharide to the protein carrier. This conjugation transforms the T-cell independent O-antigen into a T-cell dependent antigen, thereby enhancing immunogenicity and inducing long-lasting immunological memory. It was primarily developed by researchers at the National Institutes of Health (NIH) and has been evaluated in clinical trials for its safety and ability to elicit serum IgG antibodies against the Shigella lipopolysaccharide.
- Other names
- Shigella flexneri 2a-rEPA conjugate vaccineS. flexneri 2a-rEPASF2a-rEPASF-2a-rEPASF 2a-rEPA
02
Targets
S. flexneri 2a O-antigen (Shigella flexneri 2a O-antigen)
Beyond the preview
Go deeper on Shigella flexneri 2a-rEPAsucc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shigella flexneri 2a-rEPAsucc.